Back to Search
Start Over
REAL-WORLD VERSUS RANDOMIZED TRIAL OUTCOMES IN SIMILAR POPULATIONS OF RIVAROXABAN-TREATED PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN ROCKET AF AND XANTUS
- Source :
- Journal of the American College of Cardiology. 69:438
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- Background: Rivaroxaban was noninferior to warfarin in stroke or systemic embolism prevention in patients with nonvalvular atrial fibrillation (NVAF) in the ROCKET AF randomized controlled trial. Real-world evidence from XANTUS in an unselected rivaroxaban-treated NVAF population also showed low
- Subjects :
- medicine.medical_specialty
education.field_of_study
Rivaroxaban
business.industry
Population
Warfarin
Atrial fibrillation
medicine.disease
Rocket af
law.invention
Randomized controlled trial
law
Internal medicine
medicine
Cardiology
In patient
cardiovascular diseases
Cardiology and Cardiovascular Medicine
education
business
Stroke
medicine.drug
Subjects
Details
- ISSN :
- 07351097
- Volume :
- 69
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi...........3b975ef245ab3d11398030a673527520
- Full Text :
- https://doi.org/10.1016/s0735-1097(17)33827-5